Company news

Chongqing Genrix Biopharmaceutical Co., Ltd. Class A (SSE:688443) news

Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 16, 2026: "CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement…

Chongqing Genrix Biopharmaceutical Co., Ltd. Class A (SSE:688443) news

Press releases & updates

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Chongqing Jurisdiction and Semi-annual Performance Briefing

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Conditional Approval for Marketing of Velinotamig Injection

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 Injection for the Indication of Chronic Hepatitis B

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 Injection

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application

Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus

Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on License Agreement for the GR1803 Project

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection (Subcutaneous Injection)

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Renewing Engagement of Audit Institution for 2026

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026

Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 Restricted Stock Incentive Plan

Notice on Convening the 2nd Extraordinary General Meeting in 2026

Announcement on Opening of a New Special Account for Raised Funds and Signing of a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Voluntary Disclosure on Acceptance of Marketing Application for Tallecimab Injection for Adult Seasonal Allergic Rhinitis

Announcement on Resolutions of the 6th Meeting of the 2nd Board of Directors

Earnings Preannouncement for 2025

Announcement on Resignation of Independent Director

Announcement on Voluntary Disclosure of Inclusion GR1803 Injection in the List of Priority Review Drugs

Announcement on Voluntary Disclosure on the Acceptance of Conditional Listing Application for GR1803 Injection

Announcement on Changing Signatory Certified Public Accountant

Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog

关于董事辞任暨选举职工代表董事的公告

Announcement on Resolutions of the 5th Meeting of the 2nd Board of Directors

Announcement on Voluntary Closure of the Commercialization Cooperation for Vecantoxatug Monoclonal Antibody Injection and Silevimig Monoclonal Antibody Injection

Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Chongqing Jurisdiction and Semi-Annual Performance Briefing

Announcement on Voluntary Disclosure on the Acceptance of Talizumab Injection

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection for the Treatment of Systemic Lupus Erythematosus

Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR2303 Injection

Announcement on Resolutions of the 3rd Meeting of the 2nd Board of Supervisors

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1802 Injection Indicated for Adolescent Seasonal Allergic Rhinitis

Announcement on Voluntary Disclosure of Initiation of Phase 3 Clinical Trial of GR1802 for Indications for Allergic Rhinitis Treatment

Announcement on Resignation of Senior Management Member and Adjustment of Core Technical Personnel

Announcement on Implementation Result of Shares Repurchase and Share Changes

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Silevimig Injection

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection Combined with Anti-CD38 Monoclonal Antibody for Indications of Adult Patients with Relapsed/Refractory Multiple Myeloma

Announcement on Progress in Repurchasing Shares

Announcement on Resolutions of the 2024 Annual General Meeting

Announcement on Initial Public Offering of Restricted Shares under Strategic Allotment for Circulation

Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for GR2001 Injection

Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing

Notice on Convening the 2024 Annual General Meeting

Preliminary Earnings Estimate for 2024